ClinicalTrials.Veeva

Menu

Idiopathic Pulmonary Fibrosis and Serum Bank (FPI)

R

Rennes University Hospital

Status

Completed

Conditions

Lung Diseases, Interstitial
Idiopathic Pulmonary Fibrosis

Treatments

Biological: Blood sample collection

Study type

Observational

Funder types

Other

Identifiers

NCT04016168
35RC14_9722
2014-A00268-39 (Other Identifier)

Details and patient eligibility

About

Idiopathic pulmonary fibrosis (IPF) is the most common form of chronic idiopathic diffuse interstitial lung disease (DILD) in adults. It is a fibroproliferative, irreversible disease of unknown cause, usually progressive, occurring mainly from the age of 60 and limited to the lungs. IPF is a serious disease with a median survival rate at diagnosis of 3 years.

The aim of the study is to set up a biocollection of serum from patients in a context of idiopathic DILD and a possible or confirmed diagnosis of common interstitial lung disease by chest CT.

Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.

Full description

This study will initially focus on circulating serum CD163 markers, but a broader proteomics approach could be considered in a second phase to look for other markers of lung diseases.

Enrollment

903 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients seen on an outpatient basis and in stable or acute condition
  • Patient over 18 years of age.
  • The inclusion criteria will be those edited by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) to diagnosis IPF

Exclusion criteria

  • Patients who are unable or unwilling to sign the consent.

Trial design

903 participants in 1 patient group

Patients with DILD
Description:
Patients will be recruited at the consultations of the Rennes Rare Lung Disease Competence Centre. These will be patients in stable condition or in acute exacerbation of IPF.
Treatment:
Biological: Blood sample collection

Trial contacts and locations

1

Loading...

Central trial contact

Stéphane JOUNEAU, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems